161 related articles for article (PubMed ID: 32347768)
1. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
2. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
[TBL] [Abstract][Full Text] [Related]
3. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
4. Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model.
Ren K; Wang W; Sun S; Hou X; Hu K; Zhang F
Cancer Med; 2022 Jan; 11(1):257-267. PubMed ID: 34779587
[TBL] [Abstract][Full Text] [Related]
5. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
[TBL] [Abstract][Full Text] [Related]
7. Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.
Reboux PA; Azaïs H; Canova CH; Bendifallah S; Ouldamer L; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Collinet P; Bricou A; Huchon C; Daraï E; Ballester M; Lévêque J; Lavoué V; Koskas M; Uzan C; Canlorbe G
J Gynecol Oncol; 2019 Jul; 30(4):e53. PubMed ID: 31074238
[TBL] [Abstract][Full Text] [Related]
8. Pattern of recurrence in patients with endometrial cancer: A retrospective study.
Vizza E; Cutillo G; Bruno V; Sperduti I; Mancini E; Baiocco E; Chiofalo B; Cicchillitti L; Certelli C; Zampa A; Piccione E; Corrado G
Eur J Surg Oncol; 2020 Sep; 46(9):1697-1702. PubMed ID: 32204935
[TBL] [Abstract][Full Text] [Related]
9. Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis.
Wang W; Zou L; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Sun S; Jin M; Zhang F; Hou X; Wei L; Hu K
BMC Cancer; 2021 Jul; 21(1):774. PubMed ID: 34217240
[TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
[TBL] [Abstract][Full Text] [Related]
11. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
12. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
Garzon S; Grassi T; Mariani A; Kollikonda S; Weaver AL; McGree ME; Petersen IA; Weroha SJ; Glaser GE; Langstraat CL; Amarnath SR; AlHilli MM
Gynecol Oncol; 2022 Dec; 167(3):444-451. PubMed ID: 36244826
[TBL] [Abstract][Full Text] [Related]
13. Practice patterns of adjuvant radiotherapy in women with stage I to II endometrial carcinoma: a real-world multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Womens Health; 2023 Aug; 23(1):417. PubMed ID: 37553639
[TBL] [Abstract][Full Text] [Related]
14. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
Bendifallah S; Ilenko A; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy.
Diavolitsis V; Rademaker A; Lurain J; Hoekstra A; Strauss J; Small W
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):415-9. PubMed ID: 22365625
[TBL] [Abstract][Full Text] [Related]
16. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
17. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis.
Gupta V; McGunigal M; Prasad-Hayes M; Kalir T; Liu J
Gynecol Oncol; 2017 Jan; 144(1):119-124. PubMed ID: 27793358
[TBL] [Abstract][Full Text] [Related]
19. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
20. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]